Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

New treatment for type 1 diabetics gives hope to University of Chicago patients

Key Takeaway: A new treatment for type 1 diabetes has emerged, providing hope for patients at the University of Chicago. The innovative approach aims to transform the lives of those living with this chronic condition. With promising results, the treatment could significantly enhance the quality of life for many individuals affected by diabetes.
Price reaction · baseline $2.62 (2024-10-04 close) · 1 other ELDN headline(s) in the window, move may be shared
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • New treatment offers hope for type 1 diabetes patients.
  • University of Chicago patients are optimistic about the results.
  • Potential for significant improvement in patient lives.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

Transforming Lives. One Organ at a Time.
• Overview Focus Patient Stories Clinical Trials In The News
• Science Mechanism of Action Pipeline Publications & Presentations In The News
• Team Overview Leadership Board of Directors
• Investors Overview News & Events Press Releases Events Publications & Presentations Corporate Governance Governance Overview Committee Composition Ethics Hotline Financials SEC Filings Stock Information Stock Quote & Chart Analyst Coverage Resources Investor FAQs Email Alerts Contact IR
• Culture/Careers Culture Careers
• Contact
• Focus
• Patient Stories
• Clinical Trials
• In The News
• Mechanism of Action
• Pipeline
• Publications & Presentations
• In The News
• Overview
• Leadership
• Board of Directors
• Overview
• News & Events Press Releases Events Publications & Presentations
• Corporate Governance Governance Overview Committee Composition Ethics Hotline
• Financials SEC Filings
• Stock Information Stock Quote & Chart Analyst Coverage
• Resources Investor FAQs Email Alerts Contact IR
• Press Releases
• Events
• Publications & Presentations
• Governance Overview
• Committee Composition
• Ethics Hotline
• SEC Filings
• Stock Quote & Chart
• Analyst Coverage
• Investor FAQs
• Email Alerts
• Contact IR
• Culture
• Careers
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What is the new treatment for type 1 diabetes?

The new treatment aims to provide significant improvements for patients with type 1 diabetes.

Where is this treatment being offered?

The treatment is being offered at the University of Chicago.

Who can benefit from this new treatment?

Patients living with type 1 diabetes are the primary beneficiaries of this treatment.

What impact does the treatment have on patients?

The treatment has the potential to transform the lives of individuals affected by diabetes.

Last updated: Oct 6, 2024